Annual report for Natco Pharma Ltd. for FY-2019
27-05-2019
Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earning call for Q4FY19 and FY19 on 28th May, 201922-05-2019
Natco Pharma Ltd - 524816 - Closure of Trading Window
Trading window closed from 18th May 2019 to 29th May 201918-05-2019
NATCO PHARMA LTD. - 524816 - Board Meeting Intimation for Approval Of Audited Results, Considering 3Rd Interim Dividend And Convening 36Th AGM And Related Matters
NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2019 ,inter alia, to consider and approve 1. Approval of Audited Financial Results for the quarter and year ended March 31, 2019 2. Considering 3rd Interim Dividend for the financial year 2018-2019 3. Convening of the 36th AGM and related matters18-05-2019
Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Post Buyback Public Announcement
The post offer public advertisement regarding completion of the Buyback17-05-2019
Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Closure of Buy Back
Natco Pharma Limited has informed the Exchange regarding Closure of Buy Back on May 16, 201916-05-2019
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Natco's marketing partner Alvogen receives FDA approval for Nitroglycerin Sublingual Tablets08-05-2019
NATCO PHARMA LTD. - 524816 - Certificate Under Regulation 74(5) Of SEBI (Depositories And Participants) Regulations, 2018
certificate under regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the period ended 31st March, 201906-05-2019
Company news: Natco Pharma
Natco Pharma has announced final approval of the Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration for Bosentan tablets02-05-2019
Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Natco & its alliance partner Lupin receive FDA approval for generic Bosentan Tablets02-05-2019